Repare Therapeutics to Participate in Two Upcoming Investor Conferences
November 06 2023 - 7:00AM
Business Wire
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq:
RPTX), a leading clinical-stage precision oncology company, today
announced that members of its senior management team will
participate at two investor conferences in November. Details for
the fireside chats are as follows:
Stifel 2023 Healthcare Conference Date: Tuesday, November
14, 2023 Time: 8:35 a.m. Eastern Time Location: New York, NY
Piper Sandler 35th Annual Healthcare Conference Date:
Tuesday, November 28, 2023 Time: 10:30 a.m. Eastern Time Location:
New York, NY
A live webcast of the fireside chats can be accessed in the
Investor section of the Company’s website at
https://ir.reparerx.com/news-and-events/events. A replay of the
webcast will be archived on the Company’s website for at least 30
days.
About Repare Therapeutics, Inc.
Repare Therapeutics is a leading clinical-stage precision
oncology company enabled by its proprietary synthetic lethality
approach to the discovery and development of novel therapeutics.
The Company utilizes its genome-wide, CRISPR-enabled SNIPRx®
platform to systematically discover and develop highly targeted
cancer therapies focused on genomic instability, including DNA
damage repair. The Company’s pipeline includes lunresertib (also
known as RP-6306), a PKMYT1 inhibitor currently in Phase 1 clinical
development; camonsertib (also known as RP-3500 or RG6526), a
potential leading ATR inhibitor currently in Phase 1/2 clinical
development and partnered with Roche; RP-3467, a preclinical Polθ
inhibitor program; as well as several additional, undisclosed
preclinical programs, including RP-1664. For more information,
please visit reparerx.com and follow @Reparerx on X (formerly
Twitter) and LinkedIn.
SNIPRx® is a registered trademark of Repare Therapeutics
Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231106081922/en/
Repare Contact: Steve Forte Executive Vice-President and
Chief Financial Officer Repare Therapeutics Inc.
investor@reparerx.com
Investors: Matthew DeYoung Argot Partners
repare@argotpartners.com
Media: David Rosen Argot Partners
david.rosen@argotpartners.com 212-600-1902
Repare Therapeutics (NASDAQ:RPTX)
Historical Stock Chart
From Apr 2024 to May 2024
Repare Therapeutics (NASDAQ:RPTX)
Historical Stock Chart
From May 2023 to May 2024